BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nadunolimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nadunolimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06548230-2923@assetmemo.bio
DTSTAMP:20261121T010125Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nadunolimab: Phase 1/2 readout est. (NCT06548230)
DESCRIPTION:Nadunolimab\, phase 1/2.\nStudy: A Phase 1B/2A Trial of NADUNOL
 IMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients
  With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)\
 nEstimated primary completion: 1 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nadunolimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06548230
URL:https://assetmemo.bio/drug/nadunolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284485-2923@assetmemo.bio
DTSTAMP:20261121T010125Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Nadunolimab: Phase 2 readout est. (NCT07284485)
DESCRIPTION:Nadunolimab\, phase 2.\nStudy: Immunoprevention for High-risk L
 ung Lesions\nEstimated primary completion: 15 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nadunolimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07284485
URL:https://assetmemo.bio/drug/nadunolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281716-2923@assetmemo.bio
DTSTAMP:20261121T010125Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Nadunolimab: Phase 1/2 readout est. (NCT07281716)
DESCRIPTION:Nadunolimab\, phase 1/2.\nStudy: Combination Immunotherapy for 
 the Treatment of Chemotherapy-refractory Metastatic MSS CRC\nEstimated pri
 mary completion: 15 December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nadunolimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07281716
URL:https://assetmemo.bio/drug/nadunolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
